血管運動神経症状（VMS）の世界市場規模、シェア、成長分析：治療タイプ別、流通チャネル別、地域別 - 産業予測、2024-2031年

血管運動神経症状（VMS）の世界市場の2022年の市場規模は35億米ドルと評価され、予測期間（2024-2031年）のCAGRは6.90%で、2023年の37億4,000万米ドルから2031年には63億8,000万米ドルに達すると予測されています。

ほてり、寝汗、貧血などの血管運動神経症状（VMS）は、月経中によく見られ、突然の発汗や顔の赤みを引き起こすことがよくあります。これらの症状は閉経後の女性の間で頻度や強度が大きく異なり、一般的に閉経後2年間が最も課題となります。これらの症状の重症度は日常生活に支障をきたすほどで、特定の女性にとってはいつまでも続くこともあり、月経の過程が多様で個人的なものであることが強調されています。多面的な神経症状は、女性が人生のこの時期に遭遇する特有の課題に対処するための包括的なサポートの必要性を強調しています。

目次

イントロダクション

• 調査の目的
• 定義
• 市場範囲

調査手法

• 情報調達
• 二次データソースと一次データソース
• 市場規模予測
• 市場の想定と制限

エグゼクティブサマリー

• 市場概要見通し
• 供給需要動向分析
• セグメント別機会分析

市場力学と見通し

• 市場力学
  • 促進要因
  • 機会
  • 抑制要因
  • 課題
• ポーターの分析

主な市場の考察

• 技術分析
• バリューチェーン分析
• 価格分析
• スタートアップ分析
• 規制情勢
• 特許分析
• パイプライン分析
• 重要成功要因
• 市場の魅力指数
• 競合の程度
• 主な投資機会
• エコシステムマッピング

血管運動神経症状（VMS）市場：治療タイプ別

• 市場概要
• ホルモン
• 非ホルモン

血管運動神経症状（VMS）市場：流通チャネル別

• 市場概要
• 病院薬局
• 小売薬局
• オンラインストア
• その他

血管運動神経症状（VMS）市場規模：地域別

• 市場概要
• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ（MEA）
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ地域

競合情勢

• 上位5社の比較
• 主要企業の市場ポジショニング（2023年）
• 主な市場企業が採用した戦略
• 市場における最近の活動
• 主要企業の市場シェア（2023年）

主要企業プロファイル

• Astellas Pharma Inc.（Japan）
• Pfizer Inc.（United States）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• AbbVie Inc.（United States）
• GlaxoSmithKline plc（United Kingdom）
• Johnson & Johnson（United States）
• Merck & Co., Inc.（United States）
• Sanofi S.A.（France）
• Eli Lilly and Company（United States）
• Novo Nordisk A/S（Denmark）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Amgen Inc.（United States）
• Roche Holding AG（Switzerland）
• Bristol-Myers Squibb Company（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Mylan N.V.（United States）
• Allergan plc（Ireland）
• Endo International plc（Ireland）
• Sun Pharmaceutical Industries Ltd.（India）

Vasomotor Symptoms Market was valued at USD 3.5 billion in 2022 and is expected to rise from USD 3.74 billion in 2023 to reach a value of USD 6.38 billion by 2031, at a CAGR of 6.90% during the forecast period (2024-2031).

Vasomotor symptoms, such as hot flashes, night sweats, and anaemia, are commonly experienced during menstruation, often causing sudden sweating and facial redness. These symptoms vary greatly in frequency and intensity among postmenopausal women, with the initial two years post-menopause typically being the most challenging. The severity of these symptoms can be incapacitating, and for certain women, they may persist indefinitely, underscoring the diverse and personal nature of the menstrual journey. The multifaceted neurological symptoms emphasize the necessity for comprehensive support to address the unique challenges women encounter during this phase of life.

Top-down and bottom-up approaches were used to estimate and validate the size of the Vasomotor Symptoms market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Vasomotor Symptoms Market Segmental Analysis

The vasomotor symptoms market is segmented into therapy type, distribution channel, and region. Based on therapy type, the market is segmented into Hormonal (Estrogen, Progesterone, Combination, Others), Non-Hormonal (Anti-Depressants, Others). Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, online stores and others. Based on region, the market is segmented into North America, Asia Pacific, Europe, Middle East & Africa, and Latin America.

Drivers of the Vasomotor Symptoms Market

Research and development (R&D) initiatives and clinical trials are pivotal in advancing our comprehension of the fundamental causes of neurological symptoms, encompassing mutations and physiological processes. This deeper insight holds the potential to facilitate the development of more precise and efficient therapies. By delving deeper into the complexities of neurological disorders through clinical trials, researchers can contribute significantly to the market's robust compound annual growth rate (CAGR). These trials not only broaden the spectrum of available treatment modalities but also stimulate market expansion by introducing novel therapeutic approaches.

Restraints in the Vasomotor Symptoms Market

The expansion of the market is constrained by the substantial expenses linked with diverse treatment approaches. Numerous stakeholders dedicate considerable resources to advancing treatment methodologies, aiming to improve recovery processes, which inevitably drives up overall expenses. These investments encompass research, development, and manufacturing, all contributing to the escalated costs of various treatment modalities. Despite the potential benefits in enhancing patient outcomes and treatment effectiveness, the heightened financial burdens pose a significant hurdle to the market's growth trajectory.

Market Trends of the Vasomotor Symptoms Market

The introduction of new interventions or the development of innovative treatments has the potential to raise awareness about vasomotor symptoms (VMS) and underscore the significance of effective treatment options. This heightened awareness can prompt more women to actively seek relief for their symptoms, thereby expanding the market for VMS treatments. Companies specializing in launching new products or treatments for VMS can potentially gain a competitive edge in this market. This advantage is particularly crucial for establishing their product as the preferred choice among healthcare providers and patients alike, solidifying its position in the treatment landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Pricing Analysis
• Start Up Analysis
• Regulatory Landscape
• Patent Analysis
• Pipeline Analysis
• Key Success Factors
• Market Attractiveness Index
• Degree of Competition
• Top Investment Pockets
• Ecosystem Mapping

Vasomotor Symptoms Market by Therapy Type

• Market Overview
• Hormonal
• Non-Hormonal

Vasomotor Symptoms Market by Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others

Vasomotor Symptoms Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Endo International plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments